Board Meeting18 Jul 2026, 04:40 pm
Rossari Biotech Board Approves Q1 FY27 Unaudited Results, ESOP Grant
AI Summary
Rossari Biotech Ltd's Board of Directors convened on July 18, 2026, approving the unaudited financial results for the quarter ended June 30, 2026 (Standalone and Consolidated). The Board also approved the grant of 4000 stock options under the ESOP 2019 plan and the allotment of 2500 equity shares upon exercise of options. Additionally, the company approved the transfer of its 100% shareholding in Rossari International Limited Company to Rossari (Singapore) Pte. Ltd. as part of an internal group restructuring. The results were subjected to a limited review by statutory auditors.
Key Highlights
- Board approved unaudited financial results for Q1 FY27.
- Approved grant of 4000 stock options under ESOP 2019.
- Allotted 2500 equity shares upon ESOP option exercise.
- Approved transfer of subsidiary Rossari International Limited Company.
- Transfer is part of internal group restructuring for overseas subsidiaries.
Price Impact
More from ROSSARI